Gritstone bio (GRTS) Competitors

+0.04 (+5.35%)
(As of 05/17/2024 ET)


Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Athira Pharma (ATHA), JATT Acquisition (JATT), Protalix BioTherapeutics (PLX), Elutia (ELUT), Precision BioSciences (DTIL), Cognition Therapeutics (CGTX), AlloVir (ALVR), Instil Bio (TIL), Passage Bio (PASG), and CEL-SCI (CVM). These companies are all part of the "biological products, except diagnostic" industry.

Gritstone bio vs.

Gritstone bio (NASDAQ:GRTS) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.

Gritstone bio received 122 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 69.31% of users gave Gritstone bio an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.

Gritstone bioOutperform Votes
Underperform Votes
Athira PharmaOutperform Votes
Underperform Votes

Athira Pharma has a net margin of 0.00% compared to Gritstone bio's net margin of -926.13%. Athira Pharma's return on equity of -80.59% beat Gritstone bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Gritstone bio-926.13% -232.42% -79.96%
Athira Pharma N/A -80.59%-67.70%

Gritstone bio currently has a consensus target price of $5.33, indicating a potential upside of 577.33%. Athira Pharma has a consensus target price of $19.00, indicating a potential upside of 653.97%. Given Athira Pharma's higher probable upside, analysts clearly believe Athira Pharma is more favorable than Gritstone bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gritstone bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
Athira Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)

In the previous week, Gritstone bio had 3 more articles in the media than Athira Pharma. MarketBeat recorded 14 mentions for Gritstone bio and 11 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.61 beat Gritstone bio's score of 0.24 indicating that Athira Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gritstone bio
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Athira Pharma
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

48.5% of Gritstone bio shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 4.6% of Gritstone bio shares are held by company insiders. Comparatively, 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gritstone bio has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, meaning that its share price is 183% more volatile than the S&P 500.

Athira Pharma has lower revenue, but higher earnings than Gritstone bio. Athira Pharma is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone bio$16.34M5.23-$138.49M-$1.24-0.63
Athira PharmaN/AN/A-$117.67M-$3.05-0.83


Athira Pharma beats Gritstone bio on 9 of the 16 factors compared between the two stocks.

Get Gritstone bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTS vs. The Competition

MetricGritstone bioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$85.49M$2.96B$5.17B$7.96B
Dividend YieldN/A2.18%44.01%3.91%
P/E Ratio-0.6313.50118.4515.56
Price / Sales5.23377.552,367.4177.86
Price / CashN/A160.8536.4531.98
Price / Book6.067.215.754.76
Net Income-$138.49M-$43.47M$105.79M$217.17M
7 Day Performance0.37%4.26%1.39%2.90%
1 Month Performance5.88%9.96%4.28%6.57%
1 Year Performance-58.99%7.86%7.71%10.17%

Gritstone bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Athira Pharma
2.2022 of 5 stars
-8.7%$84.33MN/A-0.7165Earnings Report
Analyst Forecast
News Coverage
JATT Acquisition
0 of 5 stars
N/A+13.9%$82.63MN/A0.002,021Gap Up
High Trading Volume
Protalix BioTherapeutics
3.3679 of 5 stars
N/A$85.05M$65.49M29.00208Earnings Report
Analyst Revision
1.8225 of 5 stars
N/A$81.06M$24.75M-1.4154Short Interest ↑
Gap Up
Precision BioSciences
4.0713 of 5 stars
-44.4%$80.41M$48.73M-0.72109Analyst Forecast
Analyst Revision
Cognition Therapeutics
3.3706 of 5 stars
+12.6%$79.32MN/A-2.1525Positive News
1.488 of 5 stars
-81.3%$88.76MN/A-0.42112Analyst Revision
News Coverage
Instil Bio
3.2653 of 5 stars
-4.4%$77.22MN/A-0.6349Positive News
Passage Bio
2.263 of 5 stars
+34.4%$91.19MN/A-0.7158Analyst Forecast
Analyst Revision
News Coverage
0 of 5 stars
N/AN/A$74.76MN/A-2.04N/AEarnings Report
Gap Up

Related Companies and Tools

This page (NASDAQ:GRTS) was last updated on 5/18/2024 by Staff

From Our Partners